News | April 08, 2023
Emcure Pharmaceuticals bags Merit Award at HIV Congress 2023
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
At present 18 per cent of the local pharmaceutical market is under government's price control
Subscribe To Our Newsletter & Stay Updated
